drug development, clinical trials

The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.

The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.

A review by the US Office of Inspector General found that only about half of the scientists running clinical trials funded by the NIH in 2019 and 2020 appropriately recorded their findings in a federal database, as is legally required.

No deaths had previously been associated with the muscle-wasting treatment Zolgensma.

A lack of comprehension among some researchers about how to use ClinicalTrials.gov may be hindering public access to trial information and holding up drug study results, an investigation by The Scientist finds.

The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.

Too often, studies that aim to develop new treatments for patients fail to adequately cite and build upon research that preceded them.

The country’s provisional go-ahead could increase pressure already being exerted on the US Food and Drug Administration to approve the therapy.

How scientists aim to induce an immune response against addictive drugs

Researchers are turning to the immune system for help in treating addiction and preventing overdose.

Testing in animals and lab-grown cells suggests the experimental drug could enhance the function of lysosomes within cells.

The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.

A first-of-its-kind gene therapy dramatically reduced misfolded protein levels in some clinical trial participants for up to six months and reduced levels in all participants for up to a year.

A new regulation and registry covering investigational medicinal products mandates reporting and supports multinational trials.

Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.

Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.

The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.

Pradipta Ghosh has plans to revolutionize the drug discovery pipeline.

An unfolded protein found in human milk shows promise in early clinical trials to treat bladder cancer.